There are a couple of developments in the BMY front that are pushing shares higher:
Bristol-Myers Squibb: US FDA Accepts Ixabepilone Application
Bristol-Myers Wins Plavix Ruling
Interesting, though, that Cowen recommended selling into strength, according to an entry on theflyonthewall.com. BMY briefly poked above $32, but is now trading around $31.55.